CDKN2A gene inactivation in epithelial sporadic ovarian cancer

被引:0
作者
D Niederacher
H-Y Yan
H-X An
H G Bender
M W Beckmann
机构
[1] Heinrich-Heine-University,Department of Obstetrics and Gynaecology
[2] The Third Affiliated Hospital of Hebei Medical University,Department of Obstetrics and Gynaecology
来源
British Journal of Cancer | 1999年 / 80卷
关键词
gene; LOH; 9p21–22; RT-PCR; immunohistochemistry; ovarian cancer;
D O I
暂无
中图分类号
学科分类号
摘要
The tumour suppressor gene CDKN2A, located on chromosome 9p21, encodes the cell cycle regulatory protein p16. Inactivation of the CDKN2A gene could lead to uncontrolled cell growth. In order to determine the role of CDKN2A in the development of sporadic ovarian cancer, loss of heterozygosity at 9p21–22, homozygous deletion, mutation and methylation status of the CDKN2A gene as well as CDKN2A expression were examined in a panel of serous papillary ovarian cancer. The frequency of loss of heterozygosity (LOH) for one or more informative markers at 9p21–22 was 65% (15/23). The most common deleted region was located between interferon (IFN)-α and D9S171. Homozygous deletions and mutations of the CDKN2A gene were not found. There was no evidence of methylation in exon 1, but methylation in exon 2 of CDKN2A gene was found in 26% (6/23). Absence of CDKN2A gene expression was shown in 27% (6/22) at mRNA level and 21% (4/19) at protein level. These data suggest that the CDKN2A gene is involved in the tumorigenesis of ovarian cancer, but the mechanisms of CDKN2A gene inactivation in serous papillary ovarian cancer remains unclear.
引用
收藏
页码:1920 / 1926
页数:6
相关论文
共 220 条
  • [11] An H-X(1996)High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci Br J Cancer 73 420-423
  • [12] Niederacher D(1997)Increased expression of cyclin-dependent Chinese inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis Int J Cancer (Pred Oncol) 74 57-63
  • [13] Köhrer K(1995)Loss of heterozygosity on chromosome 9 in human breast cancer: association with clinical variables and genetic changes at other chromosome regions Int J Cancer 64 378-382
  • [14] Finken-Eigen M(1997)Alteration of p16 and p15 genes in common epithelial ovarian tumors Int J Cancer 74 148-1550
  • [15] Schröder W(1996)Cyclin E, a redudant cyclin in breast cancer Proc Natl Acad Sci USA 93 15215-15220
  • [16] Schnürch HG(1995)Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing Cancer Res 55 4531-4535
  • [17] Bender HG(1995)Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies J Urol 154 1954-1957
  • [18] Beckmann MW(1994)A cell cycle regulator potentially involved in genesis of many tumor types Science 264 436-440
  • [19] Picard F(1995)Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers J Natl Cancer Inst 87 1224-1229
  • [20] An HX(1996)Hypermethylation of the p16 gene in nasopharyngeal carcinoma Cancer Res 56 2721-2725